INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
11/03/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Snapshot rápido
ELANIX
ST13
US500000079212480Classe
Pedido
Registro
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Titulares
Representantes
Lisa M. DuRoss Harness, Dickey & Pierce, PLC
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 3
Cosmetic preparations, namely, preparations for cleaning, protecting and maintaining in good condition various parts of the human and animal body surface; cosmetic preparations for regeneration of the skin and mucous membranes; cosmetic preparations for personal use
Classe 5
Pharmaceutical, biological or biotechnological products for curing or treating dermatological, gynecological and orthopedic conditions namely, pharmaceutical preparations for treating dermatological, gynecological and orthopedic conditions; wound dressing containing foetal cell based/derived proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins; wound dressing containing foetal cell based/derived proteins for which the cells were cultured in conditions as to produce these proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins for orthopaedic implants; pharmaceutical, biological or biotechnological preparations, namely, specialty medicated cosmetic creams, wound dressings, implantable scaffolds comprising living tissue for enhancing therapy or maintaining tissue contour, and cell derivatives being stem cells for medical use for tissue regeneration; pharmaceutical, biological or biotechnological preparations for medical use for treatment ofgynecological illnesses; biological or biotechnological preparations for medical use for treatment of orthopedic injuries; Pharmaceutical, biological or biotechnological preparations for medical use for activating cellular functions namely, for treatment of foetal cell derived structural and adhesion proteins to alter immune responses or enhance wound healing, growth supplements for manufacturing of cell therapies
Classe 9
Software for medical applications for diagnosing and monitoring tissue healing in dermatology, orthopedics, and gynecology
Classe 10
Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organically derived but non-living scaffold materials alone or in combination with cells or cell derivatives to protect the skin and heal skin related conditions, burns, ulcers, cuts, and surgical incisions; Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with non-living cell derivatives to protect the skin and heal skin related conditions burns, ulcers, cuts, and surgical incisions; Matrices for tissue regeneration in the nature of implantable dermatology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices for tissue regeneration in the nature of implantable gynecology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices for tissue regeneration comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration in the nature of implantable orthopedic scaffolds comprising artificial or non- living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration
Classe 40
Custom manufacture of cosmetic preparations, pharmaceutical preparations and/or chemical preparations for use in industry, intermediate and finished formulations, and single constituents; Custom manufacture of biological tissue and of biotechnological products for use in research; Custom manufacture of cosmetics to order and according to customer requirements; Custom manufacture for others of biological production platforms, biotechnology production platforms for protein production, mammalian and human cells for protein production, organoid production for testing purposes, to order and according to customer requirements
Classe 42
Scientific research consulting services provided by consultants in the fields of pharmaceutical, biological, biotechnological, medical and cosmetic research, preclinical and safety assessments
Classe 44
Medical services and providing of medical information in the medical field; Medical testing and analysis for diagnostic purposes; Medical consultation services provided by consultants relating to pharmaceutical, biological, biotechnological, cosmetic and medical products
Histórico de despachos e eventos da marca no USPTO.
49 publicações encontradas
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
11/03/2026
CANCELLED SECTION 71
11/07/2025
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
25/12/2023
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/07/2022
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/07/2022
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/07/2022
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
11/07/2022
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/07/2022
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/07/2022
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/07/2022
FINAL DECISION TRANSACTION PROCESSED BY IB
26/04/2019
FINAL DISPOSITION NOTICE SENT TO IB
05/04/2019
FINAL DISPOSITION PROCESSED
05/04/2019
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/03/2019
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/01/2019
REGISTERED-PRINCIPAL REGISTER
25/12/2018
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
19/12/2018
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
19/12/2018
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/10/2018
PUBLISHED FOR OPPOSITION
09/10/2018
NOTIFICATION PROCESSED BY IB
06/10/2018
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
19/09/2018
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
19/09/2018
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/09/2018
APPROVED FOR PUB - PRINCIPAL REGISTER
04/09/2018
EXAMINER'S AMENDMENT ENTERED
31/08/2018
ASSIGNED TO LIE
31/08/2018
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
31/08/2018
EXAMINERS AMENDMENT E-MAILED
31/08/2018
EXAMINERS AMENDMENT -WRITTEN
31/08/2018
NEW REPRESENTATIVE AT IB RECEIVED
07/06/2018
NOTIFICATION OF FINAL REFUSAL EMAILED
01/03/2018
FINAL REFUSAL E-MAILED
01/03/2018
FINAL REFUSAL WRITTEN
01/03/2018
TEAS/EMAIL CORRESPONDENCE ENTERED
14/02/2018
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/02/2018
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/02/2018
REFUSAL PROCESSED BY IB
01/09/2017
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
17/08/2017
REFUSAL PROCESSED BY MPU
17/08/2017
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/08/2017
NON-FINAL ACTION WRITTEN
31/07/2017
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
29/07/2017
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
24/07/2017
NON-FINAL ACTION WRITTEN
23/07/2017
APPLICATION FILING RECEIPT MAILED
18/07/2017
ASSIGNED TO EXAMINER
14/07/2017
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/07/2017
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/07/2017
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.